This article will address Ocinaplon, a current topic that has aroused the interest of different sectors of society. Ocinaplon has gained relevance in recent times and has generated a debate around its implications and repercussions. Through an exhaustive analysis, we will seek to offer a complete and objective view of Ocinaplon, in order to provide readers with a deeper understanding of this topic. In addition, different perspectives and approaches will be examined that will allow Ocinaplon to be approached from different angles, thus enriching the knowledge and debate around this topic.
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H11N5O |
Molar mass | 301.309 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Ocinaplon is an anxiolytic drug in the pyrazolopyrimidine family of drugs. Other pyrazolopyrimidine drugs include zaleplon and indiplon.
Ocinaplon has a similar pharmacological profile to the benzodiazepine family of drugs, but with mainly anxiolytic properties and relatively little sedative or amnestic effect.
A 2019 review found tentative evidence of benefit in anxiety.
The mechanism of action by which ocinaplon produces its anxiolytic effects is by modulating GABAA receptors, although ocinaplon is more subtype-selective than most benzodiazepines.
Development of ocinaplon is discontinued due to liver complications that occurred in one of the Phase III subjects.
Condensation of 4-Acetylpyridine with N,N-Dimethylformamide dimethyl acetal (DMFDMA) gives the "enamide" (3). This is then condensed with (3-Amino-1H-pyrazol-4-yl)(2-pyridinyl)methanone (4) (96219-90-8). This is the same intermediate as was used in the synthesis of zaleplon in which the nitrile is replaced by a 2-acetylpyridil moiety. This affords the anxiolytic agent ocinaplon (5).